NCT04903197 2026-04-01
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
Phase 1 Terminated
Novartis
Memorial Sloan Kettering Cancer Center
Hackensack Meridian Health
M.D. Anderson Cancer Center